pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a company based in Massachusetts, USA, has announced the receipt of approval from the FDA for its sustained release fluocinolone acetonide… Read More »pSivida Corporation receives $25M milestone payment from licensee Alimera Sciences Inc. following FDA approval of Iluvien
Ophthotech Corporation (Nasdaq:OPHT) has announced the triggering of a $50 million enrollment milestone payment from Novartis as part of a licensing and commercialization agreement focused… Read More »Ophthotech Corporation (Nasdaq:OPHT) receives $50M milestone payment from Novartis for clinical progression of Fovista
Amarantus Biosciences Holdings Inc., with bases in San Francisco, USA and Geneva, Switzerland have announced the exercise of an option to exclusively license worldwide rights… Read More »Amarantus Bioscience Holdings Inc., licenses technology from the Bascom Palmer Eye Institute
In the latest round of claim and counter-claim following a hostile takeover bid from Valeant Pharmaceuticals (NYSE: VRX) for Allergan Inc., (NYSE: AGN), Valeant and… Read More »Allergan and Valeant continue to trade blows in hostile takeover bid
Pfenex Inc., San Diego, a clinical-stage biotechnology company developing biosimilar therapeutics has closed its previously announced initial public offering of 8,333,333 shares of its common… Read More »US-based biosimilar company targeting Lucentis market announces IPO price
Avalanche Biotechnologies, Inc., (AAVL), a California-based ophthalmic gene therapy company has raised just over $102 million in its IPO debut on the US NASDAQ (July… Read More »Retinal gene therapy company, Avalanche Biotechnologies (NASDAQ:AAVL), raises $102M in IPO
Applied Genetic Technologies Corporation (NASDAQ: AGTC), Gainsville, Florida has announced the execution of a gene therapy manufacturing services agreement with the Sigma-Aldrich Corporation (NASDAQ: SIAL).… Read More »Retinal gene therapy company, Applied Genetic Technologies Corporation (NASDAQ: AGTC) partners with Sigma-Aldrich (SAFC) in AAV manufacture
Allergan Inc., (NYSE:AGN) vigorously rejected a revised unsolicited offer from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to acquire all common outstanding Allergan stock in a… Read More »Allergan defends hostile bid from Valeant Pharmaceuticals as war of words continue
Panoptes Pharma Ges.m.b.H, an Austrian biotechnology company launched in 2013, has announced that the treatment of autoimmune uveitis models with its experimental drug, PP-001, significantly… Read More »Austrian company, Panoptes Pharma, announces in vivo data for experimental uveitis drug, PP-001
Ophthotech Corporation (NASDAQ:OPHT) announced its entry into an ex-US licensing and commercialisation agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration… Read More »Ophthotech Corp signs licensing and commercialisation agreement with Novartis for anti-PDGF Fovista compound